Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Dec 29;17(1):46. doi: 10.3390/ijms17010046

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 by the authors; licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The effects of SSA treatment on mRNA levels of pro-inflammatory cytokines and IL-23 receptor (IL-23R). (A) SSA treatment suppressed the expression of TNFα, IL-17A, IL-17F, and IFNγ mRNA (p < 0.05 by Wilcoxon signed rank test); (B) SSA treatment had no effect on the levels of IL-23 and IL-23R mRNA. Real-time RT-PCR values for each inflammatory cytokine were normalized to those of 18S rRNA (p > 0.05 by Wilcoxon signed rank test). Data were obtained from six AS patients before SSA medication, after SSA medication for two months, and after SSA medication for four months, respectively.

The effects of SSA treatment on mRNA levels of pro-inflammatory cytokines and IL-23 receptor (IL-23R). (A) SSA treatment suppressed the expression of TNFα, IL-17A, IL-17F, and IFNγ mRNA (p < 0.05 by Wilcoxon signed rank test); (B) SSA treatment had no effect on the levels of IL-23 and IL-23R mRNA. Real-time RT-PCR values for each inflammatory cytokine were normalized to those of 18S rRNA (p > 0.05 by Wilcoxon signed rank test). Data were obtained from six AS patients before SSA medication, after SSA medication for two months, and after SSA medication for four months, respectively.